Condensed Consolidated Interim Financial Statements as of September 30, 2018

Bayer Group
Consolidated Income Statements

 

 

Q3 2017

 

Q3 2018

 

9M 2017

 

9M 2018

 

 

€ million

 

€ million

 

€ million

 

€ million

2017 figures restated

1

For definition see Annual Report 2017, Chapter “Alternative Performance Measures Used by the Bayer Group.”

2

Weighted average number of shares (basic and diluted) restated for all periods prior to June 2018 to reflect the effect of the bonus component of the subscription rights issued as part of the June 2018 capital increase

Net sales

 

8,025

 

9,905

 

26,419

 

28,524

Cost of goods sold

 

(2,565)

 

(4,507)

 

(8,335)

 

(10,928)

Gross profit

 

5,460

 

5,398

 

18,084

 

17,596

Selling expenses

 

(2,544)

 

(2,979)

 

(8,042)

 

(8,428)

Research and development expenses

 

(1,079)

 

(1,180)

 

(3,270)

 

(3,481)

General administration expenses

 

(485)

 

(850)

 

(1,438)

 

(1,850)

Other operating income

 

285

 

4,217

 

629

 

4,554

Other operating expenses

 

(249)

 

(183)

 

(685)

 

(307)

EBIT1

 

1,388

 

4,423

 

5,278

 

8,084

Equity-method income (loss)

 

(8)

 

(16)

 

(20)

 

82

Financial income

 

84

 

154

 

216

 

684

Financial expenses

 

(479)

 

(816)

 

(1,264)

 

(1,636)

Financial result

 

(403)

 

(678)

 

(1,068)

 

(870)

Income before income taxes

 

985

 

3,745

 

4,210

 

7,214

Income taxes

 

(212)

 

(851)

 

(894)

 

(1,561)

Income from continuing operations after income taxes

 

773

 

2,894

 

3,316

 

5,653

of which attributable to noncontrolling interest

 

(3)

 

8

 

(3)

 

14

of which attributable to Bayer AG stockholders

 

776

 

2,886

 

3,319

 

5,639

Income from discontinued operations after income taxes

 

3,423

 

 

4,628

 

of which attributable to noncontrolling interest

 

318

 

 

759

 

of which attributable to Bayer AG stockholders

 

3,105

 

 

3,869

 

Income after income taxes

 

4,196

 

2,894

 

7,944

 

5,653

of which attributable to noncontrolling interest

 

315

 

8

 

756

 

14

of which attributable to Bayer AG stockholders (net income)

 

3,881

 

2,886

 

7,188

 

5,639

 

 

 

 

 

 

 

 

 

 

 

Shares

 

Shares

 

Shares

 

Shares

Weighted average number of shares2

 

885,546,889

 

980,151,964

 

885,066,889

 

927,477,704

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Earnings per share

 

 

 

 

 

 

 

 

From continuing operations

 

 

 

 

 

 

 

 

Basic

 

0.88

 

2.94

 

3.75

 

6.08

Diluted

 

0.88

 

2.94

 

3.75

 

6.08

From discontinued operations

 

 

 

 

 

 

 

 

Basic

 

3.50

 

0.00

 

4.37

 

0.00

Diluted

 

3.50

 

0.00

 

4.37

 

0.00

From continuing and discontinued operations

 

 

 

 

 

 

 

 

Basic

 

4.38

 

2.94

 

8.12

 

6.08

Diluted

 

4.38

 

2.94

 

8.12

 

6.08

Compare to Last Year